Invion (IVX) Stock Price, News & Analysis

Company Overview

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 471,000 shs
• Average Volume: N/A
• Market Capitalization: A$10.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IVX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Invion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Invion investors own include Denbury Resources (DNR), Walt Disney (DIS), Carlisle Companies (CSL), Cyclone Metals Limited (CFE.AX) (CFE), Camtek (CAMT), BXP (BXP) and BioSpecifics Technologies (BSTC).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: ASX:IVX
• CIK: N/A
• Web: www.inviongroup.com
• Phone: 61 3 9081 6005
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$5.63 million
• Net Margins: -152.34%
• Pretax Margin: N/A
• Return on Equity: -34.85%
• Return on Assets: -20.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.05
• Quick Ratio: 18.63

Sales & Book Value

• Annual Sales: A$3.69 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 15.00
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,770,000,000
• Free Float: N/A
• Market Cap: A$10.20 million
• Optionable: Not Optionable
• Beta: 1.12